Staphefekt

Staphefekt is a proprietary enzyme (an endolysin) intended to treat Staphylococcus aureus skin infections in humans.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Staphefekt is a proprietary enzyme (an endolysin) intended to treat Staphylococcus aureus skin infections in humans. It is developed and produced by the Dutch biotechnology company Micreos. It became the first commercially available endolysin and is marketed in Gladskin products.

The enzyme has been shown to be effective in killing S. aureus strains resistant to antibiotics such as MRSA. The enzyme has successfully been used for treatment of S. aureus-related dermatosis.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1348853613 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.